Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(0.66)
# 3,788
Out of 4,749 analysts
97
Total ratings
21.35%
Success rate
-33.62%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRZN Surrozen | Initiates: Buy | $32 | $11.60 | +175.86% | 1 | Jan 30, 2025 | |
| OPT Opthea | Reiterates: Buy | $12 | $5.56 | +115.83% | 5 | Jan 29, 2025 | |
| FDMT 4D Molecular Therapeutics | Reiterates: Buy | $36 | $5.60 | +542.86% | 16 | Jan 13, 2025 | |
| OPTN OptiNose | Maintains: Buy | $5 → $18 | $5.92 | +204.05% | 6 | Jan 3, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Buy | $30 | $8.02 | +274.06% | 1 | Dec 16, 2024 | |
| PHAT Phathom Pharmaceuticals | Reiterates: Buy | $28 | $5.99 | +367.45% | 7 | Dec 12, 2024 | |
| IRD Opus Genetics | Reiterates: Buy | $8 | $1.11 | +620.72% | 1 | Dec 12, 2024 | |
| IMUX Immunic | Initiates: Buy | $10 | $0.98 | +925.64% | 1 | Nov 25, 2024 | |
| ADVM Adverum Biotechnologies | Reiterates: Buy | $30 | $4.22 | +610.90% | 4 | Nov 19, 2024 | |
| EYEN Eyenovia | Downgrades: Neutral | $12 → $2 | $0.03 | +5,680.35% | 14 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 | $6.40 | -53.13% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $5.76 | +21.53% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.61 | +645.34% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $10.30 | +191.26% | 4 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $25.53 | +48.84% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $0.18 | +994.09% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $1.97 | +1.52% | 5 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $5.24 | +90.84% | 10 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.22 | +350.45% | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $216.21 | -87.05% | 1 | Aug 22, 2023 |
Surrozen
Jan 30, 2025
Initiates: Buy
Price Target: $32
Current: $11.60
Upside: +175.86%
Opthea
Jan 29, 2025
Reiterates: Buy
Price Target: $12
Current: $5.56
Upside: +115.83%
4D Molecular Therapeutics
Jan 13, 2025
Reiterates: Buy
Price Target: $36
Current: $5.60
Upside: +542.86%
OptiNose
Jan 3, 2025
Maintains: Buy
Price Target: $5 → $18
Current: $5.92
Upside: +204.05%
Zenas BioPharma
Dec 16, 2024
Initiates: Buy
Price Target: $30
Current: $8.02
Upside: +274.06%
Phathom Pharmaceuticals
Dec 12, 2024
Reiterates: Buy
Price Target: $28
Current: $5.99
Upside: +367.45%
Opus Genetics
Dec 12, 2024
Reiterates: Buy
Price Target: $8
Current: $1.11
Upside: +620.72%
Immunic
Nov 25, 2024
Initiates: Buy
Price Target: $10
Current: $0.98
Upside: +925.64%
Adverum Biotechnologies
Nov 19, 2024
Reiterates: Buy
Price Target: $30
Current: $4.22
Upside: +610.90%
Eyenovia
Nov 18, 2024
Downgrades: Neutral
Price Target: $12 → $2
Current: $0.03
Upside: +5,680.35%
Nov 15, 2024
Reiterates: Neutral
Price Target: $3
Current: $6.40
Upside: -53.13%
Nov 15, 2024
Reiterates: Buy
Price Target: $7
Current: $5.76
Upside: +21.53%
Nov 13, 2024
Reiterates: Buy
Price Target: $12
Current: $1.61
Upside: +645.34%
Nov 12, 2024
Reiterates: Buy
Price Target: $30
Current: $10.30
Upside: +191.26%
Nov 7, 2024
Reiterates: Buy
Price Target: $38
Current: $25.53
Upside: +48.84%
Aug 15, 2024
Reiterates: Neutral
Price Target: $2
Current: $0.18
Upside: +994.09%
Aug 12, 2024
Reiterates: Neutral
Price Target: $2
Current: $1.97
Upside: +1.52%
Aug 9, 2024
Reiterates: Buy
Price Target: $10
Current: $5.24
Upside: +90.84%
Nov 14, 2023
Reiterates: Buy
Price Target: $10
Current: $2.22
Upside: +350.45%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $216.21
Upside: -87.05%